UQ scientific excellence reaches the global pipeline in landmark deal

(L-R) Professor Keith Chappell, Professor Daniel Watterson and Emeritus Professor Paul Young, inventors of the Molecular Clamp technology. (Photo credit: The University of Queensland. )

One of the world’s leading healthcare companies has completed its acquisition of the biopharmaceutical company commercialising The University of Queensland's Molecular Clamp technology. Sanofi entered into an agreement earlier this year to acquire Vicebio, a company formed in 2018 to develop UQ’s Molecular Clamp technology to make vaccines against life-threatening respiratory viral infections. The record-breaking deal, the largest involving a company commercialising intellectual property (IP) from an Australian university, is now complete.  

Read the full story on UQ News.

The National Biologics Facility is proud to have contributed to the success of the Molecular Clamp platform.